This Solicitation opportunity from Department Of Defense was posted on July 14, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
DIBUCAINE OINTMENT
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
Dibucaine Ointment, USP, containing 1 percent dibucaine as the active ingredient, is being procured by the Department of Defense through a solicitation issued by the Medical Supply Chain Pharm FSA. The product is supplied in a collapsible tube and rectal applicator for rectal administration and is intended for external use only. Each unit of issue is a package containing one ounce or 28 grams, and must be stored at temperatures between 15 and 30 degrees Celsius (59 to 86 degrees Fahrenheit). The item is regulated by the FDA and must be marked in accordance with Medical Marking Standard No. 1, superseding MIL-STD-129, with packaging and preservation conforming to MIL-STD-2073-1E and Special Packaging Instructions MPPWN00001 Rev dated 03/30/1988. The product is subject to a non-extendable 36-month shelf life under RS001 for Type I (Code Q) items. All commercial packaging must ensure protection from damage and breakage, with shipping containers suitable for common carrier delivery to the destination in Watervliet, NY, under FOB Destination terms. The solicitation requires strict compliance with the Buy American Act and DFARS 252.225-7001, and contractors must adhere to hazardous materials handling standards including FAR 52.223-3 and submission of labeling and Material Safety Data Sheets. This procurement is a simplified acquisition under NAICS Code 325412 with an award deadline of July 20, 2026, and delivery must be completed within five days after order placement. The quantity is divided across multiple CLINs totaling 25 packages (PG), with no variance permitted in delivery quantities. Inspection and acceptance occur at the destination point, and payment must be requested via Wide Area Workflow using electronic methods. Offerors must be registered in the System for Award Management (SAM), provide accurate representations of small business status regardless of set-aside designations, and comply with anti-trafficking, cybersecurity, and export control requirements. Deviations in FAR clauses 52.204-13, 52.213-4, 52.216-1, 52.216-1 Alt I, 52.219-28,
General Info
Agency
NAICS
Place of Performance
WATERVLIET ARSENAL, WATERVLIET, NY, 12189-5000, USASet-Aside
Timeline
Submission Closed
Organization & Contact Information
Full Description
DIBUCAINE OINTMENT<(>,<)> USP. CONTAINS 1 PERCENT OF DIBUCAINE OINTMENT
AS THE ACTIVE INGREDIENT. COMES SUPPLIED IN A COLLAPSIBLE TUBE AND
RECTAL APPLICATOR. RECTALLY ADMINISTERED. FOR EXTERNAL USE ONLY. UNIT OF
ISSUE IS A PACKAGE CONTAINING ONE (1) OUNCE OR 28 GRAMS. STORE AT 15-30
DEGREES CELSIUS OR 59 TO 86 DEGREES FARENHEIT.
RP001: DLA PACKAGING REQUIREMENTS FOR PROCUREMENT
RA001: THIS DOCUMENT INCORPORATES TECHNICAL AND/OR QUALITY REQUIREMENTS
(IDENTIFIED BY AN 'R' OR AN 'I' NUMBER) SET FORTH IN FULL TEXT IN THE
DLA MASTER LIST OF TECHNICAL AND QUALITY REQUIREMENTS FOUND ON THE WEB
AT:
http://www.dla.mil/HQ/Acquisition/Offers/eProcurement.aspx http://www.dla.mil/HQ/Acquisition/Offers/eProcurement.aspx
FOR SIMPLIFIED ACQUISITIONS, THE REVISION OF THE MASTER IN EFFECT ON THE SOLICITATION ISSUE DATE OR THE AWARD DATE CONTROLS. FOR LARGE ACQUISITIONS, THE REVISION OF THE MASTER IN EFFECT ON THE RFP ISSUE DATE APPLIES UNLESS A SOLICITATION AMENDMENT INCORPORATES A FOLLOW-ON REVISION, IN WHICH CASE THE AMENDMENT DATE CONTROLS.
RQ011: REMOVAL OF GOVERNMENT IDENTIFICATION FROM NON-ACCEPTED SUPPLIES
This device or drug is regulated by the FDA. Note to Buyers: The contracting official shall send a referral in EBS to the product specialist for confirmation. Please include bidder name and bidder contact information, manufacturer name, manufacturer part number, and item description.
RD003, COVERED DEFENSE INFORMATION POTENTIALLY APPLIES
RS020: Shelf-life requirement RS001 for a TYPE I (CODE Q) item with a shelf life of 36 months (non-extendable) applies to this item.
Shall be marked IAW the latest edition of Medical Marking Standard No. 1 https://www.dla.mil/Logistics-Operations/Packaging/
THE HARVARD DRUG GROUP, L.L.C. 1LEZ0 P/N NDC00536-1211-95
DLA issues this document using the DoD authorized unit of issue, please refer to the following URL to determine the corresponding ANSI X12 unit of issue.
https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fwww.dla.mil%2FPortals%2F104%2FDocuments% 2FDLMS%2FeApplications%2FLogDataAdmin%2FUnitofIssueandPurchaseUnit.xlsx&wdOrigin=BROWSELINK
CLIN PR PRLI UI QUANTITY UNIT PRICE TOTAL PRICE.
0001 7017466424 0001 PG 2.000
NSN/MATERIAL:6505002999535
DELIVERY (IN DAYS):0005
SPE2DP-26-T-4101
SECTION B
PR: 7017466424 PRLI: 0001 CONT’D
DELIVER FOB: DESTINATION
QTY VARIANCE: PLUS 0% MINUS 0%
INSPECTION POINT: DESTINATION
ACCEPTANCE POINT: DESTINATION
PREP FOR DELIVERY:
PKGING DATA MIL-STD-2073-1E
SPECIAL NSN/Part Number: 6505-00-299-9535 Quantity: 2 PG Purchase Request: 7017471615QTY: 6 Delivery: 5 days ADO
More opportunities from Department Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA
Same awarding agency
Find Active Opportunities Like This
Get AI-powered intelligence on the opportunities still open
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 650+ contractors already using CLEATUS